Navidea Biopharmaceuticals, Inc. (NAVB) financial statements (2022 and earlier)

Company profile

Business Address 4995 BRADENTON AVENUE
DUBLIN, OH 43017
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,2317,1767,1147,5072,6703,7231,617
Cash and cash equivalents4,2317,1767,1147,5072,6703,7231,617
Inventory, net of allowances, customer advances and progress billings151179179166170  
Inventory151179179166170  
Other undisclosed current assets1,0013022,7501,1543,6881,0704,449
Total current assets:5,3837,65710,0438,8286,5284,7936,066
Noncurrent Assets
Operating lease, right-of-use asset128159189220250280310
Property, plant and equipment12012611712313213421
Intangible assets, net (including goodwill)786790705679620561482
Intangible assets, net (excluding goodwill)786790705679620561482
Other noncurrent assets227227227227227227227
Total noncurrent assets:1,2621,3031,2381,2491,2301,2031,041
TOTAL ASSETS:6,6458,96011,28110,0777,7585,9967,107
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,6571,2061,0801,2341,9491,1161,161
Accounts payable1,4211,2061,0801,2341,1621,1161,161
Accrued liabilities41   32  
Employee-related liabilities1,195   755  
Debt453  191745366410
Other undisclosed current liabilities2,1892,8902,9452,7342,0212,5332,574
Total current liabilities:5,3004,0974,0254,1594,7154,0144,145
Noncurrent Liabilities
Long-term debt and lease obligation2029120209296380434
Operating lease, liability2029120209296380434
Liabilities, other than long-term debt700700700700700700700
Deferred revenue700700700700700700700
Total noncurrent liabilities:7207298209099961,0801,134
Total liabilities:6,0204,8264,8455,0685,7115,0955,279
Stockholders' equity
Stockholders' equity attributable to parent, including:(107)3,4035,7054,2781,316170(2,354)
Preferred stock, shares subscribed but unissued, subscriptions receivable   (9,550)(10,300)(14,150) 
Common stock221221221220218217216
Common stock, share subscribed but unissued, subscriptions receivable   (4,975)(4,975)(5,000)(392)
Common stock, value, subscriptions    11 
Additional paid in capital370,460370,317370,181380,605375,428375,154350,178
Accumulated deficit(370,788)(367,135)(364,698)(362,024)(359,057)(356,053)(352,748)
Other undisclosed stockholders' equity attributable to parent000100392
Stockholders' equity attributable to noncontrolling interest731731731731731731731
Total stockholders' equity:6254,1346,4365,0092,047901(1,623)
Other undisclosed liabilities and equity      3,450
TOTAL LIABILITIES AND EQUITY:6,6458,96011,28110,0777,7585,9967,107

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues5096261124219268271
Cost of revenue     (0)(0)
Gross profit:5096261124219268271
Operating expenses(3,690)(2,518)(2,931)(3,453)(3,020)(3,167)(2,611)
Operating loss:(3,639)(2,422)(2,670)(3,330)(2,801)(2,899)(2,341)
Nonoperating income (expense)(13)(0)(4)(3)(23)(1)15
Investment income, nonoperating(2)(3)1(3)(1)(0)15
Other nonoperating income (expense)(11)3(6)(0)(21)(1)(0)
Interest and debt expense  (1)363(1) (2)
Loss from continuing operations before equity method investments, income taxes:(3,652)(2,422)(2,675)(2,970)(2,824)(2,899)(2,328)
Other undisclosed income from continuing operations before income taxes    1 2
Loss from continuing operations before income taxes:(3,652)(2,422)(2,675)(2,970)(2,823)(2,899)(2,326)
Income tax expense (16)     
Loss before gain (loss) on sale of properties:(3,652)(2,438)(2,675)(2,970)(2,823)(2,899)(2,326)
Other undisclosed net income  13   
Net loss:(3,652)(2,438)(2,674)(2,967)(2,823)(2,899)(2,326)
Net income attributable to noncontrolling interest 000  0
Other undisclosed net income attributable to parent    0  
Net loss attributable to parent:(3,652)(2,438)(2,674)(2,967)(2,823)(2,899)(2,326)
Preferred stock dividends and other adjustments    (181)(406)(78)
Net loss available to common stockholders, diluted:(3,652)(2,438)(2,674)(2,967)(3,004)(3,305)(2,403)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(3,652)(2,438)(2,674)(2,967)(2,823)(2,899)(2,326)
Comprehensive loss:(3,652)(2,438)(2,674)(2,967)(2,823)(2,899)(2,326)
Comprehensive income, net of tax, attributable to noncontrolling interest 000  0
Other undisclosed comprehensive income, net of tax, attributable to parent    0  
Comprehensive loss, net of tax, attributable to parent:(3,652)(2,438)(2,674)(2,967)(2,823)(2,899)(2,326)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: